Our Commitment to Biosimilars

Learning from the past, developing for the future.

Amgen’s core focus is to discover, develop, and deliver innovative medicines for patients with serious illnesses. We are inspired every day to engineer robust and differentiated therapeutics, including biosimilars.

Biotechnology provides sophisticated ways to attack disease, and Amgen was among the first companies to recognize the potential of modern biotechnology in developing valuable medicines for patients. Now, more than 35 years later, Amgen is leveraging its biotechnology experience to the development of biosimilars. 

At the heart of Amgen’s commitment to biosimilars is our mission to serve patients. High-quality, reliably supplied biosimilars are anticipated to offer additional treatment options for patients—and we believe that we bring the highest–quality science to this new space in healthcare. 

Both development and supply of these complex medicines are expected to be scientifically challenging and capital–intensive.  Biosimilar manufacturers, like Amgen, will benefit from having significant biologics expertise, infrastructure, and investment to successfully bring these medicines to market.

That is why at Amgen we are leveraging our experience and using the same personnel, services, and manufacturing expertise from the company’s innovative business to produce high-quality, reliably supplied biosimilars for some of the most complex diseases, such as those in oncology and inflammation.

As Amgen strives towards the approval and launch of our portfolio of nine biosimilars, we look forward to adding new chapters to our story, while maintaining Amgen’s commitment to connect patients with vital medicines.1 


Frederick

Molecular Biology 34 years of experience

Christian

Drug Product Engineering 12 years of experience

Vincent

Pharmacokinetics 15 years of experience

Tamer

Analytical Sciences 21 years of experience

Kristine

Cell Line Development 14 years of experience

Shawn

Product Development 17 years of experience

Marta

Clinical Immunology 9 years of experience

Katariina

Analytical Sciences 14 years of experience

Jerad

Operations 13 years of experience

Teresa

Functional Biology 17 years of experience

Heather

Functional Biology 10 years of experience

Vladimir

Clinical Development 20 years of experience

John L

Product Quality 17 years of experience

Roy

Drug Product Engineering 8 years of experience

Junfen

Purification Processes 11 years of experience

Richard

Clinical Development 18 years of experience

Steven

Drug Product Engineering 7 years of experience

Margaret

Process Development 18 years of experience

Jyoti

Functional Biology 14 years of experience

Jennifer

Analytical Sciences 23 years of experience

Brad

Supply Chain 14 years of experience

Michael

Clinical Immunology 20 years of experience

Vineetha

Functional Biology 15 years of experience

Suresh

Process Development 18 years of experience

Darin

Product Quality 21 years of experience

Venkat

Operations 15 years of experience

Paul

Operations 15 years of experience

Susan

Product Quality 21 years of experience

Lowell

Analytical Sciences 15 years of experience

Jeff

Operations 19 years of experience

Spiro

Process Engineering 22 years of experience

Gay

Operations 20 years of experience

Primal

Clinical Development 5 years of experience

Victor

Process Development 32 years of experience

Linda

Operations 20 years of experience

Amgen is committed to biosimilars. We currently have a robust pipeline with several biosimilar molecules in development which target some of the most complex and important oncology and inflammation antibody biologics.

FIND MORE INFORMATION ON OUR PIPELINE

Reference:

  1. Data on file, Amgen; 2015.